Cholangiocarcinoma (CCA) is a malignancy that accounts for approximately 3% gastrointestinal cancer.
The aim of this study was to evaluate and compare the diagnostic value of CD56, SMAD4, CEA, and p53 biomarkers in diagnosing cholangiocarcinoma and its benign mimickers.
